Market Size – US: $50 million (Operating Room segment)
Worldwide: $100 million
Our independent lab compared our product, Stayzon™ + Bacitracin, to the market leader Bacitracin Ointment. In vitro results showed Stayzon™ + Bacitracin provided a superior barrier to bacterial growth compared to Bacitracin Ointment. Stayzon™ + Bacitracin is the only product in the world that keeps a bandage in place and delivers antibiotic to protect the surgical site area.
TEST RESULTS
Results expressed as breakthrough growth under skin (g) or no breakthrough
growth (0)
|
Test Agent |
Microorganism |
Replicates |
|||||
| 1 | 2 | 3 | 4 | 5 | 6 | ||
|
Stayzon™ |
Staphylococcus aureus |
0 |
0 |
0 |
g |
0 |
0 |
| Staphylococcus epidermidis |
0 |
0 |
0 |
0 |
0 |
0 |
|
| Enterococcus faecalis |
0 |
0 |
0 |
0 |
0 |
0 |
|
| Streptococcus pyogenes |
0 |
0 |
0 |
0 |
0 |
0 |
|
|
Bacitracin |
Staphylococcus aureus |
0 |
g |
g |
0 |
g |
g |
| Staphylococcus epidermidis |
0 |
0 |
g |
0 |
0 |
g |
|
| Enterococcus faecalis |
g |
g |
0 |
g |
g |
0 |
|
| Streptococcus pyogenes |
0 |
g |
0 |
g |
g |
0 |
|
|
Mastisol |
Staphylococcus aureus |
g |
g |
g |
g |
g |
g |
| Staphylococcus epidermidis |
g |
g |
g |
g |
g |
g |
|
| Enterococcus faecalis |
g |
g |
g |
g |
0 |
g |
|
| Streptococcus pyogenes |
g |
0 |
g |
g |
g |
g |
|
|
75% |
Staphylococcus aureus |
g |
g |
g |
g |
g |
g |
| Staphylococcus epidermidis |
g |
g |
g |
g |
g |
g |
|
| Enterococcus faecalis |
g |
g |
g |
g |
g |
g |
|
| Streptococcus pyogenes |
g |
g |
g |
g |
g |
g |
|
ART has a 5% royalty deal to distribute its post-operative topical product (Mastisol® Plus) in the $100M U.S. surgical adhesive marketplace until 2033. The product will be launched in North America by the licencee in 2016.
